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Claudio Anasetti,1 Franco Aversa,2 Claudio G. Brunstein3INTRODUCTION
Allogeneic stem cell transplantation is potentially
curative for patients with hematologic malignancy.
However, patients have only a 25% likelihood of
HLA matching with a sibling and \1% chance of
HLA matching with another relative. For patients
without a suitably matched related donor, options
include starting the search for an unrelated donor,
cord blood units, or a partial family match. The chance
of finding an ‘‘8 of 8 allele level,’’ HLA-A, -B, -C,
-DRB1 matched unrelated donor for Caucasian pa-
tients is 60% to 70%, but only 10% to 35% for U.S.
ethnic minorities. Thus, transplant centers have been
investigating novel transplant technologies for the
safer use of alternative stem cell sources in order to
provide the opportunity of allogenic stem cell trans-
plantation to all patients. Consider, for example, the
clinical scenario of a 21-year-old male who presents
with acute myeloid leukemia (AML) with deletion
chromosome 7 in first complete remission (CR1).
The patient has 1 sister who is matched for ‘‘4 of 8,’’
has multiple ‘‘7 of 8’’ but no ‘‘8 of 8’’ matched unrelated
donors, and multiple ‘‘5 of 6’’ HLA-A, -B, and -DRB1
matched cord blood units with satisfactory cell doses.
Which stem cell source would you chose?
This section will review the experience with mis-
matched unrelated donor (MMUD), haploidentical
related donor (Haplo), and unrelated umbilical cord
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Since 2008, more stem cell transplants in the
United States are performed from unrelated than
related donors, and unrelated donor transplants con-
tinue to increase toward 4000 per year, whereas the
numbers of related transplants remains steady. This
increased utilization is because of, at least in part, the
expansion of the donor registries and to the improved
transplant outcomes. In the last 25 years, the number
of donors in the registries have increased from a few
thousand to over 14 million worldwide, permitting
more patients to find a suitable match. The National
Marrow Donor Program (NMDP) and a single-
center study recently reported concordant data indi-
cating that slightly over one-half of U.S. patients find
an ‘‘8 of 8’’ and about 80% find at least a ‘‘7 of 8’’
(source: NMDP). The probability of matching and
transplantation vary with race, predominantly because
of the high HLA heterogeneity in some ethnic minor-
ities and the relative lower representation in the donor
registries. Overall survival (OS) rates at 1 year have
increased for patients with good-risk leukemia and
myelodysplasia from 39% to 65% over 20 years.
Improvements in HLA-matching techniques with bet-
ter donor selection, earlier patient referral for trans-
plantation, and improvements in supportive care are
the likely explanations for this trend (source: NMDP).
The selection of unrelated donors has undergone
radical changes over the last 20 years, as the technology
for HLA typing evolved and the role of HLAmatching
has been better understood. Although microcytotoxic-
ity testing for HLA-A, -B, and -DR loci and cellular
typing for the HLA-D region were used before 1991,
high-resolution molecular typing and matching for
HLA-A, -B, -C, and -DRB1 is the precise current stan-
dard of care [1]. Complement-dependent crossmatch-
ing of patient serum against donor cells has been
replaced by the reliable screening for donor-specific
antibodies [2].
Lee et al. [1] reported on the impact of allele level
matching at HLA-A, -B, -C, and -DRB1 on the
outcomes of unrelated donor bone marrow (BM)
transplantation. They studied 3857 patient–donorS161
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received myeloablative conditioning for the treatment
of leukemia or myelodysplasia. The key findings of this
study were that the 5-year OS for 8 of 8 allele matched
grafts (37%) was better than 7 of 8 (29%) or 6 of 8
(22%) matching. Moreover, both allele and antigen
level mismatches (except for HLA-C) adversely
impacted survival. A single mismatch increased the
mortality risk by 25% in relation to the estimate with
a matched transplant. Subgroup analysis suggested
that single mismatches atHLA-B and -Cmay be better
tolerated than HLA-A and -DRB1. Mismatch for
DQB or DPB did not affect survival of these patients
with malignancy.
Retrospective data and prospective clinical trials
showed that long-term survival after unrelated donor
BM or peripheral blood stem cell (PBSC) grafts are
similar, despite greater risk of acute and chronic
graft-versus-host disease (GVHD) after PBSC [3]
(personal communication, Dr. Claudio Anasetti).
These studies uncover the unmet need to improve on
the prevention of acute and chronic GVHD (aGVHD,
cGVHD) after T-replete grafts from unrelated do-
nors, and more so if the grafts are PBSC. In order to
better understand the impact of HLA-matching on
outcomes of unrelated donor PBSC transplantation,
Woolfrey et al. [4] conducted a detailed retrospective
analysis including 1933 patients treated between
1999 and 2006. Important differences from the study
in BM recipients [2] are the inclusion of patients re-
ceiving reduced-intensity conditioning, the lower
number of patients with chronic myeloid leukemia,
and the inclusion of diseases other than leukemia,
such as lymphomas and severe aplastic anemia, among
others. In multivariable analysis, the 1-year OS was
better for patients receiving an 8 of 8 allele level
matched compared with a 7 of 8 match unrelated do-
nor PBSC graft (56% versus 47%). Subgroup analysis
by HLA loci suggested a greater adverse impact of
a single antigen level mismatch at HLA-C. The study’s
limited power because of the small sample size pre-
cluded conclusions about other mismatches.
Despite these survival differences reaching statisti-
cal significance, the absolute survival difference was
relatively small: 5% to 10%. Hence, for patients whose
only chance for survival is an allogenic stem cell trans-
plant, and no full match is available, a 7 of 8 matched
unrelated donor is a viable option.
The advantages of a partially, 7 of 8 matched unre-
lated donor transplantation include (1) high probabil-
ity of identifying a donor, (2) adequate cell dose for
engraftment in almost all cases, (3) predictable time
to hematopoietic recovery, and (4) likely availability
of additional progenitor or immune cells if the need
arises for delayed engraftment or relapse. Limitations
of unrelated donors include (1) an HLA-matched
donor is not likely available for racial and ethnicminorities, and (2) donor selection and workup process
takes, on average, 1 month longer than for related
donors.HAPLOIDENTICAL RELATED DONOR
Interest in unmanipulated and T cell–depleted
haploidentical HSCT was reawakened by new trans-
plant strategies for GVHD prophylaxis such as
granulocyte colony stimulating factor–primed grafts,
posttransplantation sirolimus, or high-dose cyclo-
phosphamide in combination with other immunosup-
pressive agents.
In the area of unmanipulated haploidentical
HSCT, using granulocyte colony stimulating factor–
primed donor hematopoietic stem cells (HSCs) and
robust posttransplantation GVHD prophylaxis, the
Huang group in Beijing obtained a 3-year probability
of survival of 55% in 89 high-risk acute leukemia pa-
tients [5]. The corollary was very high aGVHD and
cGVHD rates. Pecatori et al. [6] developed an alterna-
tive protocol with rapamycin and mycophenolate
mofetil for GVHD prophylaxis following condition-
ing with treosulfan, fludarabine, antithymocyte globu-
lin, and a single dose of rituximab to treat 38 adults
with advanced-stage leukemia. Outcomes were not
very good, because of patients’ conditions at transplan-
tation and high treatment-related mortality (TRM)
and relapse rates, but the effects of sirolimus on regu-
latory T cell (Treg) induction and GVHD prevention
were interesting. Administering cyclophosphamide af-
ter transplantation, when the graft and host T cells rec-
ognize each other as foreign and generate bidirectional
alloreactivity, appears to be another promising way of
eliminating alloreactive T cells. It successfully reduced
GVHD and graft rejection rates, but the relapse rate
may represent a significant limitation [7]. At least in
part, this higher risk of relapse was attributed to the
nonmyeloablative conditioning, which had provided
an antileukemia effect.
The field of mismatched related donor transplan-
tation with T cell–depleted grafts has also had signifi-
cant advances. A European Blood and Marrow
Transplant retrospective study, analyzing the outcome
of HLA-haploidentical transplantation in several
European centers, reported 48% event-free survival
(EFS) in AML patients in CR1 [8]. Several reports
from the Perugia Group using high doses of peripheral
blood CD341 selected cells showed that, with follow-
ups as long as 17 years, EFS was 43% for AML patients
who were transplanted in any CR, including CR2 and
later [9]. Moreover, high-risk AML patients in CR at
transplantation who received grafts from donors who
were natural killer (NK) cell alloreactive, as deter-
mined by the missing ligand model, were associated
with a significantly lower relapse rate compared with
patients without NK alloreactive donors (3% versus
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versus 18%, P 5 .02) [10]. Interestingly, patients
whose donors were their mothers with predicted NK
cell alloreactivity offered an even better probability
of EFS [11]. Aside from achieving very good outcomes,
patients also enjoyed an excellent quality of life be-
cause they did not require posttransplantation immune
suppressive treatment and no cGVHD was observed.
Currently, themain challenge in this haploidentical re-
lated donor strategy is to accelerate immune reconsti-
tution and reduce infectious mortality in adults in the
first year posttransplantation. Promising novel adop-
tive cell therapies are under investigation. The Perugia
Group reported on the transfer of pathogen-specific T
cells for the treatment of Aspergillus and prophylaxis
cytomegalovirus (CMV) reactivation, and disease in
patients receiving haploidentical related donor grafts
[12]. The proportion of patients who resolvedAspergil-
lus infections and incidence of CMV reactivation were
significantly lower when compared with historic con-
trols who were transplanted using the same strategy
but no pathogen-specific T cells. In contrast to cells
derived from patients who did not receive pathogen-
specific T cells, clones of Aspergillus and CMV-specific
T cells obtained from the patients who received adop-
tive cell therapy expressed appropriately high levels of
interferon-g and low interleukin-10. In a follow-up
study, using the same treatment plan backbone, the
same group of investigators studied the infusion
known numbers of both Tregs and conventional T
cells (Tconv) derived from the same donor of the
CD341 selected graft [13]. The hypothesis was that
the Tregs would suppress GVHD from the
haploidentical Tconv, while giving the Tconv would
improve immune reconstitution. Patients received up
to 2  106/kg Treg with 1  106/kg Tconv without
severe aGVHD. Notably, the reconstitution of T cell
subsets, the development of antigen-specific T cells
to a variety of pathogens was improved, and the inci-
dence of CMV reactivation was lower when compared
with historic controls.
The advantages of haploidentical related donors
include (1) the fact the most patients will have a parent
or sibling as a potential donor, (2) these donors are typ-
ically readily available and highly motivated, (3) there
are additional progenitor and immune cells available
for cellular therapies, and (4) donors can often be
selected in order to achieve greater NK cell alloreac-
tivity. The disadvantages include (1) the need for either
ex vivo or in vivo T cell depletion or aggressive
immune-suppression regimens, which (2) delay im-
mune reconstitution, and (3) potentially increase the
risk of opportunistic infections and relapse.
In the case of the young patient described at the
beginning of this paper, a haplotype mismatched NK
alloreactive donor, preferably his mother, would be
a valuable alternative. Today, we are in a position tooffer a transplant to all patients with high-risk AML,
and no patient should be denied HSC transplantation
if a matched sibling donor is not available. The registry
search for a well-matched matched unrelated donor
(MUD) should not exceed 2 or 3 months. If this search
is unsuccessful, a haploidentical related donor should
be considered, preferably in the setting of a clinical
trial exploring either adoptive cell therapy, if available.UNRELATED UCB
UCB is now an accepted alternative source of
allogeneic HSC for hematopoietic reconstitution,
with more than 20,000 patients having received UCB
transplants worldwide. In this paper, we summarized
the data on UCB in the myeloablative setting.
The 2 critical factors in the selection of a UCB
graft remain the cryopreserved nucleated cell dose
(NCD) and HLA matching. Available data support
a minimum recommended cryopreserved NCD for
single UCB unit grafts of 2.5  107/kg, and units
must be 4-6 of 6 HLA-matched to the recipient
(HLA-A and -B at the antigen level and DRB1 at the
allele level) [14]. A detailed review on the selection of
UCB grafts is available [15].
In thepediatric setting,UCBhasbecomea standard
of care, in particular for the treatment of children with
acute leukemia. In children, engraftment is consistently
achieved (90%),withTRMranges from20%to40%,
and relapse and EFS ranging between 30% and 40%
[16,17]. A registry-based analysis by the Center for In-
ternational Blood and Marrow Transplant Research
compared UCB to the gold standard of 7-8 of 8
allele-matched URD donor BM grafts [16]. In this
study,UCB recipients receivedUCBgrafts selected us-
ing the current cell dose requirement standard, and re-
cipients of unrelated donor BMwereHLA-matched by
the current standards of allele level matching. As previ-
ously shown, engraftment was slower after UCB trans-
plantation. There were some differences in outcomes
when UCB was studied by HLA-matching subset
where 4 of 6 HLA-matched UCB grafts had higher
TRM but lower relapse risk, while 5-6 of 6 HLA-
matched UCB grafts had lower TRM and higher re-
lapse risk. The notable finding of this study, however,
was that leukemia-free survival (LFS) was similar be-
tween UCB grafts and unrelated BM grafts.
In the adult setting, UCB has advanced slower as
an HSC source largely because of limited ability to
find UCB units with an adequate cell dose. Still, initial
comparative studies suggested thatUCBwas a valuable
alternative for those adults with leukemia who lacked
a suitable matched unrelated donor. More recently,
a collaboration between the Center for International
Blood andMarrowTransplant Research and Eurocord
compared the outcomes of 4-6 of 6 HLA-matched
UCB grafts with a cryopreserved nucleated cell dose
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unrelated adult donors from BM and/or peripheral
blood [18]. In summary, engraftment after UCB was
delayed, which contributed, at least in part, to the
observed higher TRM among recipients of UCB.
Despite this difference in TRM, LFS was similar for
all graft types.
In order to overcome the limitation in cell dose,
larger adolescents and adult patients have been receiv-
ing UCB grafts consisting of 2 partially HLA-matched
units, a strategy called doubleUCB (dUCB) transplan-
tation. A recent collaboration between the University
of Minnesota and the Fred Hutchinson Cancer
Research Center compared the outcomes of dUCB
with those of the adult related donor, MUD, and
MMUD after total body irradiation–based myeloabla-
tive transplantation [19]. Although the combination of
2 UCB units allowed patients to proceed to transplan-
tation, similar to what has been shown in single UCB
transplantation neutrophil engraftment is delayed
after dUCB compared with adult donor grafts. TRM
was significantly higher after dUCB and was largely
influenced by delayed engraftment. For patients recov-
ering neutrophil counts before 26 days, which was the
median time to neutrophil recovery among dUCB
recipients, TRM was similar to other donor types. In
contrast, patients recovering neutrophil counts after
26 days had higher TRM. The higher TRM among
dUCB recipients was offset by a significantly lower re-
lapse risk. Although the mechanism behind the lower
relapse rate is poorly understood and requires confir-
mation in prospective trials, the net result was that
LFS was equivalent for all donor types. Two studies
recently presented in abstract form compared dUCB
with single UCB, with the graft given intravenously
[20] or by intra-BM injection (IBMI) [21]. When
both single and dUCB grafts were given intravenously
in patients with acute leukemia in first complete remis-
sion (CR1), outcomes after dUCB were improved
compared with single UCB, but there was no differ-
ence for patients in second or third CR [20]. This
was apparently because of a lower risk of relapse
among recipients of dUCB grafts. In the study com-
paring dUCB to IBMI, despite the significantly lower
total NCD in the IBMI group (2.5 versus 3.6 107/kg,
P \ .001), there was better hematopoietic recovery,
less GVHD, and better disease-free survival after
IBMI. Further studies are required to determine the
role of these and other strategies, such as UCB expan-
sion and priming with agents that promote homing, in
overcoming the cell dose limitation and improving
outcomes after UCB transplantation as reviewed
elsewhere [22].
The advantages of UCB as a source of HSC are
that (1) once a unit is identified, it is rapidly available
from the cord blood bank to proceed with transplanta-
tion; (2) because the HLA matching is less stringent,a unit can be found for most patients (4-6 of 6 HLA-
matched); (3) despite the HLA mismatching, there is
relatively low risk of GVHD; (4) there is low risk of
infection transmission; and (5) there is no risk for the
donor. The disadvantages of UCB include (1) the fixed
number of cells available in a single UCB unit with
a median of 1  109 total cells available, which may
limit the use of UCB in larger patients; (2) the delay
in hematopoietic recovery; and (3) the risk of graft fail-
ure that ranges from 5% to 15%.
Overall, these data support the use of UCB as an
alternative source of HSCs for patients who require
a potentially curative myeloablative allogeneic trans-
plant but lack a suitable related donor or an MUD.CONCLUSIONS
In conclusion, the use of these donor types has
undergone changes in the last few in years because of
technological advances in HLA typing, donor selec-
tion, supportive care, and cellular therapy. Registry-
based data showing that outcomes with these donor
types are similar to that of transplantation with an
HLA-matched related or unrelated donor are encour-
aging. Thus, for patients who lack these conventional
donors, MMUD, haploidentical, and UCB donors
are viable alternatives. Several institutions and cooper-
ative research groups, such as the Blood and Marrow
Transplantation Clinical Trials Network, are engaged
in the continued development and dissemination of the
use of these alternative donor sources.ACKNOWLEDGMENTS
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